The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) is a huge mover today! The stock decreased 5.31% or $0.3 on November 30, hitting $5.35. About 272,056 shares traded hands or 62.60% up from the average. Vascular Biogenics Ltd (NASDAQ:VBLT) has risen 74.92% since April 27, 2016 and is uptrending. It has outperformed by 69.70% the S&P500.
The move comes after 7 months negative chart setup for the $162.31 million company. It was reported on Nov, 30 by Barchart.com. We have $5.08 PT which if reached, will make NASDAQ:VBLT worth $8.12 million less.
Analysts await Vascular Biogenics Ltd (NASDAQ:VBLT) to report earnings on April, 4. They expect $-0.15 earnings per share, down 7.14% or $0.01 from last year’s $-0.14 per share. After $-0.12 actual earnings per share reported by Vascular Biogenics Ltd for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Vascular Biogenics Ltd (NASDAQ:VBLT) Ratings Coverage
Out of 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Biogenics has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) earned “Buy” rating by Roth Capital on Monday, August 24. On Tuesday, June 28 the stock rating was initiated by H.C. Wainwright with “Buy”. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. On Monday, September 21 the stock rating was initiated by Chardan Capital Markets with “Buy”. The rating was maintained by Chardan Capital Markets on Friday, October 23 with “Buy”. JMP Securities upgraded the stock to “Mkt Outperform” rating in Monday, September 21 report. The rating was maintained by Roth Capital with “Buy” on Monday, September 28. The rating was initiated by Piper Jaffray with “Overweight” on Monday, November 9.
According to Zacks Investment Research, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.”
More notable recent Vascular Biogenics Ltd (NASDAQ:VBLT) news were published by: Schaeffersresearch.com which released: “Analyst Update: Mallinckrodt PLC, Alexion Pharmaceuticals, Inc., and Vascular …” on November 29, 2016, also Globenewswire.com with their article: “Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering …” published on November 03, 2015, Globenewswire.com published: “Vascular Biogenics Ltd. Closes $24 Million Registered Direct Offering” on June 16, 2016. More interesting news about Vascular Biogenics Ltd (NASDAQ:VBLT) were released by: Investorplace.com and their article: “Vascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial” published on June 06, 2016 as well as Marketwatch.com‘s news article titled: “Virtual Stock Exchange” with publication date: October 02, 2014.
VBLT Company Profile
Vascular Biogenics Ltd., incorporated on January 31, 2000, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company’s lead product candidate, VB-111(ofranergene obadenovec), is a gene biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase II sub-study in psoriatic patients with cardiovascular risk.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.